Sermorelin
Also referenced as: GHRH (1-29), Geref
The shortest active fragment of GHRH, historically approved and used diagnostically.
- Evidence grade
- BModerate Human Evidence
Moderate Human Evidence
- Regulatory status
- FDA Approved for Specific Indication
Sermorelin acetate previously held US approval, including for paediatric growth hormone deficiency, and was later withdrawn from the US market for commercial reasons. It is widely compounded today, which is not the same as being an approved product.
- Human data
- Yes
No registered clinical trials identified
- Last reviewed
- September 1, 2026
Overview
Sermorelin is the first 29 amino acids of growth hormone releasing hormone — the minimal sequence that retains full activity at the GHRH receptor.
Its short half-life means it produces a physiological pulse of GH rather than sustained elevation, which is the main scientific argument for it over longer-acting analogues.
Why It's Being Studied
- Diagnosis of growth hormone deficiency.
- Paediatric growth hormone deficiency treatment.
- Age-related decline in GH secretion, where evidence is much weaker.
Mechanism of Action
It is the natural signal the brain uses to ask the pituitary for growth hormone, given as a short-acting injection.
Sermorelin binds the GHRH receptor on pituitary somatotrophs, raising cAMP and triggering GH release with a plasma half-life of minutes. Response depends on intact pituitary function and is modulated by somatostatin tone, preserving negative feedback.
Research Areas & Routes Studied
- Growth hormone deficiency
- GH secretion physiology
- Body composition
- Subcutaneous injection
- Intravenous (diagnostic testing)
Evidence Summary
Human studies established its use as a diagnostic and therapeutic GHRH analogue, and it held approval historically, but modern outcome evidence in adults is limited.
Human clinical evidence
- Paediatric studies supported growth velocity improvements in growth hormone deficiency.
- Adult studies report increased GH and IGF-1; clinical outcome data in healthy ageing adults are limited and inconsistent.
Observational evidence
- Compounded clinic use is widespread but poorly documented in peer-reviewed literature.
Reported Adverse Events in Research
- Injection-site pain and redness are the most common reported effects.
- Flushing, headache, dysphagia and dizziness were reported in labelled use.
Limitations of Current Evidence
- Historical approval does not validate current anti-ageing marketing.
- Requires intact pituitary function; ineffective where the pituitary is the problem.
Why It Is Used
- Growth Hormone
Body Composition and Sleep Quality
Growth-hormone secretagogues are used for the same reason across the board: better sleep first, body composition later.
Read the case study
Research References
- Narrative review
Sermorelin: a better approach to management of adult-onset growth hormone insufficiency?
- Prescribing label
Sermorelin acetate product labelling records